Drug intelligence / Profile preview

PEG-BCT-100

Development stage: Unknown
Lead developer: Bio-Cancer Treatment International
Modality: Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

PEG-BCT-100 is a PEGylated recombinant human arginase 1 (rhArg1) developed by Bio-Cancer Treatment International Limited. It is a biologic therapeutic designed to target arginine auxotrophic tumors—cancers that cannot synthesize their own arginine and depend on external sources for growth. The drug works by depleting arginine from the bloodstream, thereby starving the tumor cells. PEG-BCT-100 has been evaluated in clinical trials for several indications, including malignant melanoma, castration-resistant prostate cancer, hepatocellular carcinoma, and acute myeloid leukemia.

Brand names: BCT-100BCT100BCT 100
Other names: PEGylated recombinant human arginase 1rhArg1-pegrhArg-1-pegrhArg 1-pegpegylated arginase

Beyond the preview

Go deeper on PEG-BCT-100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PEG-BCT-100.

Explore the full profile